ANI Pharmaceuticals Inc
ANIP82.850USD
+0.020+0.02%
Fechamento 12/19, 16:00（ET）Cotações atrasadas em 15 min
1.86BValor de mercado
48.51P/L TTM
Mais detalhes de ANI Pharmaceuticals Inc Empresa
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Informações de ANI Pharmaceuticals Inc
Código da empresaANIP
Nome da EmpresaANI Pharmaceuticals Inc
Data de listagemMay 04, 2000
CEOLalwani (Nikhil Suresh)
Número de funcionários897
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
Endereço210 Main Street West
CidadeBAUDETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal56623
Telefone12186343500
Sitehttps://www.anipharmaceuticals.com/
Código da empresaANIP
Data de listagemMay 04, 2000
CEOLalwani (Nikhil Suresh)
Executivos da empresa ANI Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-11.05%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-34.62%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-6.68%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-57.96%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-12.17%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-6.53%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
60.19K
-4.31%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-16.62%
Detalhamento da receita
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
90.30M
0.00%
Sales of rare disease pharmaceutical products
81.65M
0.00%
Sales of Cortrophin Gel
81.65M
0.00%
Sales of branded pharmaceutical products
17.11M
0.00%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Outro
73.39%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.67%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
Outro
73.39%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.11%
Investment Advisor/Hedge Fund
23.24%
Hedge Fund
19.41%
Individual Investor
7.45%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.67%
Bank and Trust
1.33%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
507
21.97M
100.49%
+14.84K
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
2.37M
10.64%
-68.37K
-2.80%
Jun 30, 2025
The Vanguard Group, Inc.
1.27M
5.71%
+95.32K
+8.09%
Jun 30, 2025
Meridian Venture Partners
1.01M
4.55%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
716.12K
3.21%
+1.55K
+0.22%
Jun 30, 2025
Esjay L.L.C,
632.62K
2.84%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
862.09K
3.87%
+126.50K
+17.20%
Jun 30, 2025
UBS Financial Services, Inc.
401.55K
1.8%
+137.16K
+51.88%
Jun 30, 2025
Citadel Advisors LLC
569.63K
2.56%
-153.70K
-21.25%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
553.89K
2.48%
-77.67K
-12.30%
Jun 30, 2025
Geode Capital Management, L.L.C.
427.55K
1.92%
-2.08K
-0.48%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção2.63%
State Street SPDR S&P Pharmaceuticals ETF
Proporção2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proporção1.63%
Innovator IBD Breakout Opportunities ETF
Proporção1.38%
Innovator IBD 50 Fund ETF
Proporção1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção0.98%
Invesco S&P SmallCap Health Care ETF
Proporção0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proporção0.92%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.67%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
Perguntas frequentes
Quem são os cinco principais acionistas de ANI Pharmaceuticals Inc?
Os cinco principais acionistas de ANI Pharmaceuticals Inc são:
BlackRock Institutional Trust Company, N.A. detém 2.37M Ações, representando 10.64% do total de Ações.
The Vanguard Group, Inc. detém 1.27M Ações, representando 5.71% do total de Ações.
Meridian Venture Partners detém 1.01M Ações, representando 4.55% do total de Ações.
State Street Investment Management (US) detém 716.12K Ações, representando 3.21% do total de Ações.
Esjay L.L.C, detém 632.62K Ações, representando 2.84% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 2.37M Ações, representando 10.64% do total de Ações.
The Vanguard Group, Inc. detém 1.27M Ações, representando 5.71% do total de Ações.
Meridian Venture Partners detém 1.01M Ações, representando 4.55% do total de Ações.
State Street Investment Management (US) detém 716.12K Ações, representando 3.21% do total de Ações.
Esjay L.L.C, detém 632.62K Ações, representando 2.84% do total de Ações.
Quais são os três principais tipos de acionistas de ANI Pharmaceuticals Inc?
Os três principais tipos de acionistas da ANI Pharmaceuticals Inc são:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Meridian Venture Partners
Quantas instituições possuem ações da ANI Pharmaceuticals Inc (ANIP)?
Em 2025Q4, 507 instituições possuíam ações da ANI Pharmaceuticals Inc, com valor de mercado aproximado de 21.97M, representando 100.49% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em -2.78%.
Qual é a maior fonte de receita da ANI Pharmaceuticals Inc?
Em FY2025Q2, o segmento de negócios Sales of generic pharmaceutical products gerou a maior receita para ANI Pharmaceuticals Inc, totalizando 90.30M e representando --% da receita total.
